Plain-English translation of NCT04598009 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two medications called and work better when given together to treat advanced melanoma—a serious skin cancer that has spread or cannot be safely removed by surgery. The study focuses on melanomas with a specific genetic change (KIT mutation) that may make them respond to these medications. The research team wants to see how many people benefit from this medication combination and how safe it is.
Advanced melanoma with KIT mutations are difficult to treat, and standard treatments don't work well for everyone. Researchers believe that combining these two medications might be more effective because they target different pathways in cancer cells, potentially offering a better option for patients who haven't responded to other treatments.
You likely qualify if…
You likely don't qualify if…
You would take twice daily and once daily by mouth, with each treatment cycle lasting 28 days. You would continue this medication schedule as long as your cancer is responding and you're tolerating the medications well. You'll have regular check-in visits early on (at day 30 and 100), then every 3 months afterward, where your doctor will assess how you're doing, check for side effects, and monitor whether the treatment is working using scans or imaging.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States